Boehringer Ingelheim Boehringer Ingelheim
Corporate Site
Background
Treatment
Our Products
Symposia & Congresses
Studies & Publications
News Center
Links
Login
Actilyse®
Aggrenox®
Stroke forum -
dedicated to improving stroke therapy
Welcome to the Boehringer Ingelheim Corporate stroke website.
The site has been recently updated with an extensive amount of up-to-date information and services on stroke. Boehringer Ingelheim aims to improve the lives of stroke patients through its products and services. Our expertise lies in acute treatment and secondary prevention of stroke.
WSC Congress Vienna 2008 Over 3,000 stroke experts from all over the world met at the 6th World Stroke Congress in Vienna from 24th - 27th September and we like to offer you a summary review and webcasts of the exciting talks, lectures and teaching courses.

Please click for a short summary of the WSC

The long anticipated ECASS 3 trial results were presented by Professor W. Hacke, the principal investigator of the study.

To view the entire presentation, please visit the ESO homepage.


ECASS 3 was also a major topic of the Boehringer Ingelheim satellite symposium "Path Breaking Results in Ischaemic Stroke Therapy".

Please watch the presentations online


Results of SITS-MOST

The SITS-MOST trial was designed to determine whether treatment with intravenous alteplase within 3 hours of onset of ischaemic stroke was as safe and effective in routine clinical practice as in clinical trials. Furthermore the trial compared centres with experience in the use of thrombolysis for acute ischaemic stroke with those that were inexperienced. In January 2007, the results of SITS-MOST were published. Read a detailed summary of the results.
New: SITS-MOST slide kit
The SITS-MOST slide kit is a PowerPoint presentation on the
world’s largest stroke registry,
which was designed to determine whether the routine use of intravenous alteplase within 3 hours of onset of ischaemic stroke was as safe and effective as reported in randomised controlled trials. It contains the objective and rationale of the SITS-MOST trial, details of the trial design, baseline data and important results. A full list of references, as well as the prescribing information for Actilyse® can also be found within.

The SITS-MOST slide kit is now available for download. Please click here to obtain your own personal copy of the slide kit.
Search
Site Map
Contact
© 2003-2004 Boehringer Ingelheim GmbH, Germany. All rights reserved.
Imprint | Terms of use.